Scientists develop revolutionary eye drops to treat age-related blindness

May 15, 2017
Credit: CC0 Public Domain

Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.

The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as (AMD).

AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.

A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.

This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.

Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham's Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.

The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.

Dr de Cogan said: "The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.

"Efficacious self-administered drug application by eye would lead to a significant reduction in adverse outcomes and compared with current treatments.

"The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.

"We believe this is going to be very important in terms of empowering of patients and reducing the cost of to the NHS."

Explore further: Experimental drug shows promise for sight-stealing eye condition

More information: Felicity de Cogan et al, Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides, Investigative Opthalmology & Visual Science (2017). DOI: 10.1167/iovs.16-20072

Related Stories

Experimental drug shows promise for sight-stealing eye condition

January 19, 2017
An experimental drug may one day make treatment simpler for patients suffering from vision-threatening age-related macular degeneration, researchers say.

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma

March 16, 2017
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

Global experts discuss new approaches and innovations in ocular drug delivery systems

November 7, 2016
The estimated number of visually impaired people in the world is 285 million, with 39 million blind people. About 65 percent of visually impaired people and 82 percent of all blind people are 50 years or older. Four major ...

Gene therapy in a droplet could treat eye diseases, prevent blindness

July 27, 2016
Eye diseases such as diabetic retinopathy and age-related macular degeneration are among the leading causes of irreversible vision loss and blindness worldwide. Currently, gene therapy can be administered to treat these conditions—but ...

New hepatitis C treatments more effective, tolerable: FDA

May 11, 2017
(HealthDay)—Hepatitis C can be cured in about three months, allowing people with the viral disease to live longer, healthier lives, the U.S. Food and Drug Administration (FDA) says.

Recommended for you

Coming soon: Glaucoma self-care, from home?

September 23, 2017
(HealthDay)—For many glaucoma patients, repeat trips to a doctor's office to check on their eyes can be a real pain.

Researchers identify potential biomarkers of age-related macular degeneration

September 12, 2017
Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through special laboratory tests, according to a new study led by AMD researchers based at Massachusetts ...

Researchers unlock regenerative potential of cells in the mouse retina

August 28, 2017
Cells within an injured mouse eye can be coaxed into regenerating neurons and those new neurons appear to integrate themselves into the eye's circuitry, new research shows. The findings potentially open the door to new treatments ...

Antioxidant supplement cost saving and effective for degenerative eye disease

August 24, 2017
A supplement that combines antioxidants with zinc and copper is a relatively inexpensive and effective means of halting the progression of a certain type of degenerative eye disease, concludes research published online in ...

Researchers identify key compounds to resolve abnormal vascular growth in AMD

August 21, 2017
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers. ...

World's blind population to soar: study

August 3, 2017
The world's blind will increase threefold from about 36 million today to 115 million in 2050 as populations expand and individuals grow ever older, researchers said Thursday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.